NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

enGene Therapeutics Inc. (ENGN) Stock Analysis

enGene Therapeutics Inc. (ENGN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ENGN

$1.63

−$0.04 (−2.40%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ENGN with… →

ENGN Key Statistics

As of Oct 21, 2026
Trading
Open
$1.68
Previous Close
$1.67
Day's Range
1.59–1.68
52-Week Range
1.40–12.25
Volume
1.11M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.29
Valuation
Market Cap
$109.24M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.19
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$117.30M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
67.02M
1-Year Return
−80.82%
Dividend and dates
Earnings Date
December 22, 2026estimated
Avg Volume
748.60K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ENGN closed at $1.63, −80.82% over 1 year.

enGene Therapeutics Inc. (ENGN) has a market capitalization of $109.24M.

In fiscal 2025, ENGN reported revenue of $0.00.

ENGN Stock Return by Calendar Year

enGene Therapeutics Inc. (ENGN) return since Feb 2022: what $10,000 became

1 year
$10,000 $1,918
−80.82%
3 years
$10,000 $1,630
−83.70%
Since Feb 2022
$10,000 $1,653
−83.47%

If you had invested $10,000 in enGene Therapeutics Inc. (ENGN) at the close on February 1, 2022, the earliest close on record here, it would have been worth $1,653 at the close on October 21, 2026: −83.47% in total, −31.72% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−81.95%
2025+35.79%
2024−27.95%
2023−10.65%
2022 (partial year)+4.77%

As of October 21, 2026.

ENGN Revenue and Earnings by Fiscal Year

FY ends October
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$117.30M—
2024$0.00−$55.14M—
2023$0.00−$99.92M—
2022$0.00−$24.46M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$123.17M−$117.30M—
2024$0.00—−$62.30M−$55.14M—
2023$0.00—−$26.06M−$99.92M—
2022$0.00—−$19.43M−$24.46M—

Annual figures as reported, in the company's reporting currency. As of October 31, 2025.

Recent News

All 13 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

enGene Therapeutics Inc. (ENGN) is capitalised at $109.24M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 81 employees.

The 52-week range on file runs from $1.40 to $12.25. The most recent close on file for ENGN is $1.63, dated October 21, 2026. That is −$0.04 (−2.40%) against the previous close. The latest close sits 16.43% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $117.30M. Trailing earnings per share are −2.19.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year total return is −80.82%. Measured over 3 years, that is −45.37% a year compounded. Beta against the wider market is reported at −0.29. Annualized volatility over the trailing 4 years is 122.21%.

Growth & Income

The record shows no dividend for ENGN.

The strongest complete calendar year on file is 2025 at +35.79%; the weakest is 2024 at −27.95%. Of the 3 complete calendar years on file, 1 finished higher. So far in 2026 the total return is −81.95%.

Peer Comparison

enGene Therapeutics Inc. (ENGN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
enGene Therapeutics Inc. ENGN $109.24M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. enGene Therapeutics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About enGene Therapeutics Inc.

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.

Visit website →